Enanta Pharmaceuticals To Present Topline Results From Its Phase 2 Study Evaluating Zelicapavir For Respiratory Syncytial Virus; Conference Call And Webcast To Discuss Data On Monday, December 9 At 8:30 A.m. ET
Enanta Pharmaceuticals To Present Topline Results From Its Phase 2 Study Evaluating Zelicapavir For Respiratory Syncytial Virus; Conference Call And Webcast To Discuss Data On Monday, December 9 At 8:30 A.m. ET
enanta pharmaceuticals 將於12月9日星期一上午8:30（東部時間）召開電話會議和網絡直播，討論其評估Zelicapavir治療呼吸道合胞病毒的二期研究的初步結果。
- Conference call and webcast to discuss data on Monday, December 9 at 8:30 a.m. ET
- 電話會議和網絡廣播將於12月9日星期一上午8:30（東部時間）討論數據
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the company will hold a conference call and webcast on Monday, December 9 at 8:30 a.m. ET to share topline results from RSVPEDs, a first-in-pediatrics Phase 2 study evaluating zelicapavir in hospitalized and non-hospitalized children aged 28 days to 36 months with respiratory syncytial virus (RSV).
Enanta製藥公司（納斯達克：ENTA），一家專注於開發針對病毒學和免疫學適應症的小分子藥物的臨床階段生物技術公司，今天宣佈該公司將於12月9日星期一上午8:30（東部時間）舉行電話會議和網絡廣播，分享RSVPEDs的頂線結果，這是一項在住院和非住院28天至36個月的兒童中評估zelicapavir的第一階段2研究，該研究針對呼吸道合胞病毒（RSV）。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間